| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on July 5, 2004
Accepted on October 11, 2004
General Clinical Chemistry |
(1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice
1 Alzheimer Center and Department of Neurology, and Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
2 Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
3 Innogenetics NV, Ghent, Belgium
4 Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlandsy
Background: Reported concentrations of amyloid-
(1-42) (A42) and tau in cerebrospinal fluid (CSF) differ among reports. We investigated the effects of storage temperature, repeated freeze/thaw cycles, and centrifugation on the concentrations of A42 and tau in CSF.
Methods: Stability of samples stored at -80 °C was determined by use of an accelerated stability testing protocol according to the Arrhenius equation. A42 and tau concentrations were measured in CSF samples stored at 4, 18, 37, and -80 °C. Relative CSF concentrations (%) of the biomarkers after one freeze/thaw cycle were compared with those after two, three, four, five, and six freeze/thaw cycles. In addition, relative A42 and tau concentrations in samples not centrifuged were compared with samples centrifuged after 1, 4, 48, and 72 h.
Results: A42 and tau concentrations were stable in CSF when stored for a long period at -80 °C. CSF A42 decreased by 20% during the first 2 days at 4, 18, and 37 °C compared with -80 °C. CSF tau decreased after storage for 12 days at 37 °C. After three freeze/thaw cycles, CSF A42 decreased 20%. CSF tau was stable during six freeze/thaw cycles. Centrifugation did not influence the biomarker concentrations.
Conclusions: Repeated freeze/thaw cycles and storage at 4, 18, and 37 °C influence the quantitative result of the A42 test. Preferably, samples should be stored at -80 °C immediately after collection.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  N A Verwey, W M van der Flier, K Blennow, C Clark, S Sokolow, P P De Deyn, D Galasko, H Hampel, T Hartmann, E Kapaki, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem, May 1, 2009; 46(3): 235 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Betsou, R. Barnes, T. Burke, D. Coppola, Y. DeSouza, J. Eliason, B. Glazer, D. Horsfall, C. Kleeberger, S. Lehmann, et al. Human Biospecimen Research: Experimental Protocol and Quality Control Tools Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1017 - 1025. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tapiola, I. Alafuzoff, S.-K. Herukka, L. Parkkinen, P. Hartikainen, H. Soininen, and T. Pirttila Cerebrospinal Fluid {beta}-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain Arch Neurol, March 1, 2009; 66(3): 382 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Bouwman, W. M. van der Flier, N.S.M. Schoonenboom, E. J. van Elk, A. Kok, F. Rijmen, M. A. Blankenstein, and P. Scheltens Longitudinal changes of CSF biomarkers in memory clinic patients Neurology, September 4, 2007; 69(10): 1006 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. de Jong, R. W. M. M. Jansen, B. P. H. Kremer, and M. M. Verbeek POTENTIAL PITFALLS IN THE ANALYSIS OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 924 - 925. [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Bouwman, W. M. van der Flier, N. S.M. Schoonenboom, E. J. van Elk, A. Kok, P. Scheltens, and M. A. Blankenstein Usefulness of Longitudinal Measurements of {beta}-Amyloid1-42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. Clin. Chem., August 1, 2006; 52(8): 1604 - 1606. [Full Text] [PDF]
|
|
|
|
|
|
P. Lewczuk, G. Beck, H. Esselmann, R. Bruckmoser, R. Zimmermann, M. Fiszer, M. Bibl, J. M. Maler, J. Kornhuber, and J. Wiltfang Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid {beta} Peptides Clin. Chem., February 1, 2006; 52(2): 332 - 334. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Banks, A. J. Stanley, D. A. Cairns, J. H. Barrett, P. Clarke, D. Thompson, and P. J. Selby Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry Clin. Chem., September 1, 2005; 51(9): 1637 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S.M. Schoonenboom, C. Mulder, H. Vanderstichele, Y. A.L. Pijnenburg, G. J. Van Kamp, P. Scheltens, P. D. Mehta, and M. A. Blankenstein Differences and Similarities between Two Frequently Used Assays for Amyloid {beta} 42 in Cerebrospinal Fluid Clin. Chem., June 1, 2005; 51(6): 1057 - 1060. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
